Novo Nordisk Trial Success Triggers 23% Slump in Agios Pharmaceuticals

Shares of Agios Pharmaceuticals (AGIO) fell 23% on Monday following the release of clinical trial results from industry giant Novo Nordisk (NVO). The volatility was triggered by the Phase 3 HIBISCUS trial of Novo's etavopivat, an oral, once-daily pyruvate kinase-R (PKR) activator designed to treat sickle cell disease. Novo Nordisk reported that etavopivat became the first in its class to meet both co-primary endpoints. The treatment demonstrated a statistically significant reduction in vaso-occlusive crises (VOC), with the time to the first VOC occurring at 38.4 weeks in the treatment group compared to 20.9 weeks in the placebo group. Additionally, the drug showed a positive hemoglobin response. These results stand in stark contrast to the data released by Agios in November for its own PKR activator, mitapavit. While mitapavit also improved hemoglobin levels, it failed to demonstrate a statistically significant improvement in its primary endpoint: the annualized rate of sickle cell pain crises (SCPCs) compared to a placebo. As a result of these findings, Novo Nordisk intends to file for FDA approval in the second half of 2026. Agios, meanwhile, remains in discussions with the FDA to align on the confirmatory clinical trials required for its own submission. This discrepancy in trial success and regulatory timelines has created a significantly more uncertain path to market for Agios, leading to the sharp sell-off in its equity.